Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Payments to Acquire Debt Securities, Available-for-Sale

Payments to Acquire Debt Securities, Available-for-Sale at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$192.76M-38.0%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's payments to acquire debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's payments to acquire debt securities, available-for-sale?
Halozyme Therapeutics (HALO) reported payments to acquire debt securities, available-for-sale of $8.85M in Q1 2026.
How has Halozyme Therapeutics's payments to acquire debt securities, available-for-sale changed year-over-year?
Halozyme Therapeutics's payments to acquire debt securities, available-for-sale decreased by 93.7% year-over-year, from $139.64M to $8.85M.
What is the long-term trend for Halozyme Therapeutics's payments to acquire debt securities, available-for-sale?
Over 4 years (2021 to 2025), Halozyme Therapeutics's payments to acquire debt securities, available-for-sale has grown at a -21.5% compound annual growth rate (CAGR), from $652.52M to $247.36M.